VANCOUVER, BC – In a landmark achievement poised to redefine the treatment landscape for pediatric cancer, a pan-Canadian research team has unveiled a revolutionary approach to quickly identify personalized therapies for young patients battling aggressive and rare forms of the disease. By ingeniously combining the advanced study of proteins with a unique method of growing patient tumours in chicken eggs, researchers have demonstrated a rapid and effective pathway to pinpoint crucial treatment options, even when conventional methods fail. This groundbreaking work, led by experts from the University of British Columbia (UBC) and BC Children’s Hospital Research Institute (BCCHR), marks the first time in Canada that these two innovative techniques have been successfully integrated to inform and impact a young patient’s treatment within a clinically relevant timeframe.
The success story, detailed today in the prestigious journal EMBO Molecular Medicine, underscores the profound potential of proteomics – the comprehensive analysis of proteins – as a vital complement to the well-established field of genomics (the study of genes) in the high-stakes arena of real-time cancer therapies. This collaborative triumph is a testament to the power of national cooperation, spearheaded by PROFYLE (PRecision Oncology For Young peopLE), a cornerstone initiative of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). Bringing together over 30 research and funding organizations and more than 100 investigators from across Canada, PROFYLE’s mission is singular: to dramatically improve outcomes for children and young adults facing cancer.
The Unyielding Challenge of Pediatric Cancer
Pediatric cancer presents a unique and formidable challenge in oncology. Unlike adult cancers, which are often linked to lifestyle and environmental factors, childhood cancers frequently arise from genetic mutations that occur early in development, making them inherently different in their biology and response to treatment. They are also significantly rarer, comprising less than 1% of all cancer diagnoses, which complicates research, clinical trials, and the development of specialized therapies. The standard treatment protocols, while often effective, can also be incredibly harsh on a child’s developing body, leading to significant long-term side effects and secondary cancers.
For a subset of young patients, particularly those diagnosed with rare or aggressive forms that resist initial chemotherapy, the outlook can be grim. When standard-of-care treatments falter, oncologists often turn to advanced molecular profiling, typically focusing on genomics, to identify specific genetic mutations that could be targeted by precision drugs. However, even with the most sophisticated genetic analyses, some tumours remain stubbornly elusive, offering no clear path forward. It is in this desperate scenario that the new Canadian breakthrough offers a beacon of hope, providing a novel framework for discovery and intervention.
A Patient’s Desperate Fight: The Genesis of Innovation
The genesis of this innovation lies in the urgent need to find a solution for an unnamed patient, a young individual grappling with a rare pediatric cancer. This patient’s journey mirrored the heartbreaking reality faced by many: initial conventional treatments, including standard chemotherapy, proved ineffective. The tumour demonstrated a terrifying resilience, resisting the therapies designed to eradicate it. In a bid to find an alternative, the medical team turned to genomics, hoping to uncover a genetic vulnerability that could be exploited by an existing targeted drug.
While genomic testing is a powerful tool that has revolutionized cancer treatment, it sometimes falls short. In this particular case, despite thorough genetic sequencing, no clear or actionable drug candidates emerged. The tumour, bafflingly complex, offered no obvious genetic Achilles’ heel. The conventional avenues had been exhausted, and the family, along with their medical team, faced the agonizing prospect of having no further treatment options. It was at this critical juncture that the collaborative PROFYLE team, demonstrating remarkable foresight and scientific audacity, decided to pivot their strategy, turning their attention from the blueprint of genes to the dynamic machinery of proteins.
Proteomics: Unlocking the Tumour’s Hidden Weaknesses
While genes (DNA) provide the instructions for building and operating our cells, it is proteins that carry out virtually all cellular functions. Proteins are the "workhorses" of the cell – enzymes that drive biochemical reactions, structural components that give cells shape, and receptors that communicate with the outside world. Crucially, most cancer drugs exert their therapeutic effect by interacting with and altering the activity of specific proteins. This fundamental distinction is precisely what makes proteomics such a powerful, yet historically underutilized, tool in clinical oncology.
"While genomics alone, in this particular case, couldn’t provide a clear treatment option, we hypothesized that by looking at the tumour’s proteins, we might uncover hidden metabolic weaknesses that genetic testing alone might miss," explained Dr. Philipp Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR and a co-senior author on the study. His intuition proved prescient. The research team, including co-lead authors Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab, embarked on a deep proteomic analysis of the patient’s tumour.
Their meticulous investigation revealed a critical metabolic vulnerability: the tumour’s aggressive growth was heavily reliant on an enzyme called SHMT2 (serine hydroxymethyltransferase 2). SHMT2 plays a vital role in the cellular metabolism of serine and glycine, amino acids crucial for nucleotide synthesis – the building blocks of DNA and RNA. In rapidly proliferating cancer cells, the demand for these building blocks is exceptionally high, making enzymes like SHMT2 metabolic bottlenecks. By inhibiting SHMT2, the researchers reasoned, they could effectively cut off a key energy and building-block supply line to the tumour, essentially starving it into submission.
The beauty of this discovery lay not only in identifying the target but also in finding an existing, already approved drug that could hit it. The researchers’ strategy was to repurpose sertraline, a common antidepressant, which was known to inhibit SHMT2. This drug repurposing approach significantly shortens the timeline for clinical application, bypassing the lengthy and expensive process of developing entirely new drugs. The potential to use an existing, well-tolerated medication for a new oncological indication offered an immediate, actionable pathway forward for the patient.
The Avian Avatars: Rapid Drug Testing in Real-Time
Identifying a potential drug candidate is only half the battle; validating its efficacy against a specific patient’s tumour is the crucial next step. Traditionally, this might involve culturing tumour cells in a lab, which often fails to replicate the complex tumour microenvironment, or using mouse models, which are time-consuming and expensive. The Canadian team employed an innovative and remarkably swift solution: the "chicken egg avatar" model.
This method involves carefully grafting a small piece of the patient’s tumour tissue onto the chorioallantoic membrane (CAM) of a developing chicken embryo. The CAM is a highly vascularized extraembryonic membrane that provides an ideal environment for the human tumour xenograft to grow and develop its own blood supply. Within weeks, the tumour fragment establishes itself and grows, essentially creating a living, identical "avatar" of the patient’s original tumour outside their body.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," explained Dr. James Lim, also a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR and a co-senior author. "We could quickly confirm whether the drug we identified through proteomics – in this case, sertraline – could actually work for the patient’s specific tumour."
The chicken egg avatar model offers several distinct advantages. It maintains much of the tumour’s original heterogeneity and microenvironment, providing a more accurate representation of how it might behave in the patient. Crucially, the turnaround time is incredibly fast, allowing for personalized drug response testing in a matter of weeks, a critical factor when dealing with aggressive, fast-progressing cancers in children. These avian avatars are a key component of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, which actively bridges the gap between clinical needs and research laboratory capabilities within the hospital system.
On the chicken egg avatars, the researchers tested sertraline and observed its inhibitory effect on the tumour’s growth, confirming that the drug could indeed target the SHMT2 enzyme and disrupt the tumour’s metabolism. This rapid, in-vivo validation provided the necessary evidence to support the clinical recommendation.
A Collaborative Triumph: The Pan-Canadian Network
The ability to move from a desperate clinical situation to a validated treatment recommendation in such a short timeframe is a testament not only to the scientific ingenuity of the researchers but also to the robust, collaborative infrastructure provided by PROFYLE and ACCESS. PROFYLE, established as a flagship initiative, is specifically designed to accelerate precision oncology for young people across Canada. It creates a national network that enables rapid sharing of patient samples, clinical data, and research expertise, breaking down geographical and institutional barriers that often impede rare disease research.
The PROFYLE network facilitated the multidisciplinary collaboration essential for this breakthrough, bringing together molecular biologists, oncologists, pathologists, bioinformaticians, and other specialists. Once the research team had identified sertraline as a promising candidate and validated it on the egg avatars, they presented their comprehensive findings to a panel of experts convened by PROFYLE. This national tumour board, comprised of leading pediatric oncologists and scientists, rigorously reviewed the evidence, weighing the potential benefits against the risks. After careful deliberation, the PROFYLE expert panel concluded that sertraline represented the best available treatment option for the patient at that critical juncture, endorsing the innovative approach.
This collaborative model is the essence of ACCESS, which strives to advance the entire spectrum of childhood cancer experience, science, and survivorship. By fostering such extensive collaboration, ACCESS and PROFYLE ensure that cutting-edge research findings are rapidly translated into actionable clinical strategies, directly impacting patient care across the country.
The Patient’s Response and Future Horizons
Following the PROFYLE panel’s recommendation, the patient began treatment with sertraline. While the results were encouraging, they were not a complete cure. The patient’s tumour growth slowed significantly, indicating that the drug was indeed having a therapeutic effect and successfully targeting the metabolic weakness identified by proteomics. However, the tumour did not fully regress, signifying that additional treatment strategies would eventually be needed.
"While there is more work to be done, this study unequivocally shows that our integrated approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," affirmed Dr. Lange. The outcome, though not a definitive cure, provided valuable time and improved quality of life for the patient, a significant victory in the face of previously exhausted options. It validated the entire innovative pipeline, from proteomic discovery to egg avatar validation and expert panel endorsement.
The implications of this Canadian breakthrough extend far beyond a single patient. The study provides compelling evidence for the routine integration of proteomics alongside genomics in precision oncology, particularly for cases where genetic profiling alone is insufficient. It highlights the power of drug repurposing, offering a faster route to new treatments by identifying novel applications for existing, safe medications. Furthermore, the chicken egg avatar model stands out as a rapid, cost-effective, and ethically sound platform for personalized drug screening, potentially revolutionizing how treatment responses are evaluated in real-time for individual patients.
Looking ahead, the research team is optimistic about expanding this method. "We now hope to expand this method to other children to identify effective treatments faster across the country," stated Dr. Lange. The goal is to refine and scale this combined approach, making it more widely accessible to pediatric oncology centres across Canada and, ultimately, around the world. Further research will undoubtedly focus on exploring combinations of drugs, investigating mechanisms of resistance that might lead to incomplete responses, and continually improving the proteomic and avatar technologies.
This Canadian innovation represents a pivotal moment in the fight against childhood cancer. It embodies the relentless spirit of scientific inquiry and the profound impact of collaborative research, offering a renewed sense of hope for young patients and their families facing the most challenging diagnoses. By peering deeper into the molecular intricacies of cancer and leveraging ingenious biological models, researchers are forging a new path towards truly personalized and timely care, promising a brighter future for the next generation of cancer survivors.
About the Author
